Abstract
GPR55 is an orphan G protein-coupled receptor that may be engaged by some lipid ligands such as lysophosphatidylinositol and cannabinoid-type compounds. Very little is known about its expression pattern and physio-pathological relevance, and its pharmacology and signaling are still rather controversial. Here we analyzed the expression and function of GPR55 in cancer cells. Our data show that GPR55 expression in human tumors from different origins correlates with their aggressiveness. Moreover, GPR55 promotes cancer cell proliferation, both in cell cultures and in xenografted mice, through the overactivation of the extracellular signal-regulated kinase cascade. These findings reveal the importance of GPR55 in human cancer, and suggest that it could constitute a new biomarker and therapeutic target in oncology.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Brown AJ, Robin Hiley C . (2009). Is GPR55 an anandamide receptor? Vitam Horm 81: 111–137.
Buchholz M, Braun M, Heidenblut A, Kestler HA, Kloppel G, Schmiegel W et al. (2005). Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 24: 6626–6636.
Caffarel MM, Sarrio D, Palacios J, Guzman M, Sanchez C . (2006). Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 66: 6615–6621.
Daly C, Ross R, Whyte J, Henstridge C, Irving A, McGrath J . (2010). Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and ‘cannabinoid-like’ receptors in small arteries. Br J Pharmacol 159: 787–796.
Dorsam RT, Gutkind JS . (2007). G-protein-coupled receptors and cancer. Nat Rev Cancer 7: 79–94.
Elston EW, Ellis IO . (1993). Method for grading breast cancer. J Clin Pathol 46: 189–190.
Falasca M, Corda D . (1994). Elevated levels and mitogenic activity of lysophosphatidylinositol in k-ras-transformed epithelial cells. Eur J Biochem 221: 383–389.
Falasca M, Iurisci C, Carvelli A, Sacchetti A, Corda D . (1998). Release of the mitogen lysophosphatidylinositol from H-Ras-transformed fibroblasts; a possible mechanism of autocrine control of cell proliferation. Oncogene 16: 2357–2365.
Ford LA, Roelofs AJ, Anavi-Goffer S, Mowat L, Simpson DG, Irving AJ et al. (2010). A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160: 762–771.
Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM et al. (2004). Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64: 6503–6510.
Hazzalin CA, Mahadevan LC . (2002). MAPK-regulated transcription: a continuously variable gene switch? Nat Rev Mol Cell Biol 3: 30–40.
Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ . (2009). The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 23: 183–193.
Henstridge CM, Balenga NA, Schroder R, Kargl JK, Platzer W, Martini L et al. (2010). GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 160: 604–614.
Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS et al. (2009). Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284: 29817–29827.
Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K . (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105: 2699–2704.
Murph M, Tanaka T, Liu S, Mills GB . (2006). Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clin Cancer Res 12: 6598–6602.
Oka S, Kimura S, Toshida T, Ota R, Yamashita A, Sugiura T . (2010). Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J Biochem 147: 671–678.
Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T . (2007). Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362: 928–934.
Oka S, Toshida T, Maruyama K, Nakajima K, Yamashita A, Sugiura T . (2009). 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem 145: 13–20.
Pietr M, Kozela E, Levy R, Rimmerman N, Lin YH, Stella N et al. (2009). Differential changes in GPR55 during microglial cell activation. FEBS Lett 583: 2071–2076.
Ross RA . (2009). The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 30: 156–163.
Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092–1101.
Sawzdargo M, Nguyen T, Lee DK, Lynch KR, Cheng R, Heng HH et al. (1999). Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 64: 193–198.
Seno K, Okuno T, Nishi K, Murakami Y, Yamada K, Nakamoto S et al. (2001). Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative ‘pyrrophenone’. Bioorg Med Chem Lett 11: 587–590.
Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP et al. (2008). The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139: 225–236.
Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S et al. (2006). Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 9: 287–300.
Waldeck-Weiermair M, Zoratti C, Osibow K, Balenga N, Goessnitzer E, Waldhoer M et al. (2008). Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci 121: 1704–1717.
Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ et al. (2009). The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci USA 106: 16511–16516.
Worzfeld T, Wettschureck N, Offermanns S . (2008). G(12)/G(13)-mediated signalling in mammalian physiology and disease. Trends Pharmacol Sci 29: 582–589.
Xu Y, Xiao YJ, Baudhuin LM, Schwartz BM . (2001). The role and clinical applications of bioactive lysolipids in ovarian cancer. J Soc Gynecol Investig 8: 1–13.
Yin H, Chu A, Li W, Wang B, Shelton F, Otero F et al. (2009). Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem 284: 12328–12338.
Acknowledgements
We are indebted to the members of our laboratory for technical support and critical discussions on this work. CA and MMC were recipients of fellowships from Ministerio de Ciencia e Innovación and from Fundación Ferrer para la Investigación, respectively. MS and ML were recipients of contracts (Research Formation and Postdoctoral, respectively) from Comunidad de Madrid. This work was supported by grants from Fondo de Investigaciones Sanitarias (C Sánchez), Fundación Mutua Madrileña (C Sánchez), Ministerio de Ciencia e Innovación (G Velasco and M Guzmán), Comunidad de Madrid (M Guzmán) and GW Pharmaceuticals/Otsuka Pharmaceuticals (C Sánchez).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Andradas, C., Caffarel, M., Pérez-Gómez, E. et al. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30, 245–252 (2011). https://doi.org/10.1038/onc.2010.402
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.402
Keywords
This article is cited by
-
Deprogramming metabolism in pancreatic cancer with a bi-functional GPR55 inhibitor and biased β2 adrenergic agonist
Scientific Reports (2022)
-
Peptide targeting of lysophosphatidylinositol-sensing GPR55 for osteoclastogenesis tuning
Cell Communication and Signaling (2021)
-
Expression of the putative cannabinoid receptor GPR55 is increased in endometrial carcinoma
Histochemistry and Cell Biology (2021)
-
Immune-related genes in tumor-specific CD4+ and CD8+ T cells in colon cancer
BMC Cancer (2020)
-
Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates
Brain Structure and Function (2020)